Dual HER2 inhibition: Is two better than one?

Area of Science:

• Oncology
• Gastroenterology
• Immunotherapy

Background:

• HER2-positive (HER2+) gastroesophageal cancer is a significant clinical challenge.
• Current treatment strategies for HER2+ gastroesophageal cancer often involve HER2-targeted therapies.
• Novel therapeutic approaches are needed to improve outcomes in this patient population.

Purpose of the Study:

• To evaluate the efficacy and safety of a dual HER2-targeting strategy in frontline HER2+ gastroesophageal cancer.
• To explore the combination of HLX22, HLX02 (trastuzumab biosimilar), and capecitabine/oxaliplatin chemotherapy.

Main Methods:

• A randomized frontline phase II clinical trial was conducted.
• Patients with HER2+ gastroesophageal cancer were enrolled.
• Treatment arms included the combination of HLX22, HLX02, and chemotherapy.

Main Results:

• The combination therapy demonstrated encouraging objective response rates.
• Progression-free survival data were also positive.
• Safety and tolerability profiles require further assessment.

Conclusions:

• Dual HER2 targeting with HLX22 and HLX02 in combination with chemotherapy shows promise in HER2+ gastroesophageal cancer.
• The clinical utility and future development of this combination strategy warrant further investigation.
• The competitive landscape of HER2-targeted therapies presents challenges for new combinations.